Clinical Trial Update: Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia [Phase 3]

View source ↗

Summary

Phase 3 outcomes study completed; FocaSThStatin residual risk reduction with EPA in high cardiovascular risk patients with hypertriglyceridemia completed with p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease
• Hypertriglyceridemia

Drugs mentioned

• Epanova (icosapent ethyl)

Snippet

Sponsor: AstraZeneca | Conditions: Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD) | Phase 3 | Status: COMPLETED | Results posted: 2021-07-28